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Abstract—Alzheimer’s Disease (AD) is a widespread neurode-
generative disease caused by structural changes in the brain
and leads to deterioration of cognitive functions. Patients usually
experience diagnostic symptoms at later stages after irreversible
neural damage occurs. Therefore, early detection of AD is crucial
to start treatments to decelerate the progress of the disease and
to maximize patients’ quality of life. With the rapid advances in
machine learning and scanning, early detection of AD may be
possible via computer-assisted systems using neuroimaging data.
Among all, deep learning utilizing magnetic resonance imaging
(MRI) has become a prominent tool due to its capability to extract
high-level features through local connectivity, weight sharing,
and spatial invariance. This paper describes our investigation
of the classification accuracy based on two publicly available
data sets, namely, ADNI and OASIS, by building a 3D VGG
variant convolutional network (CNN). We used 3D models to
avoid information loss, which occurs during the process of slicing
3D MRI into 2D images and analyzing them by 2D convolutional
filters. We also conducted a pre-processing of the data to enhance
the effectiveness and classification performance of the model. The
proposed model achieved 73.4% classification accuracy on ADNI
and 69.9% on OASIS dataset with 5-fold cross-validation (CV),
outperforming 2D network models.
Index Terms—Alzheimer’s Disease, Deep Learning, Image
Classification, 3D CNN, MRI, Neuroimaging
I. INTRODUCTION
Alzheimer’s Disease (AD) is the most common type of
dementia, which is caused by the deterioration of cognitive
and memory functions [1]. Pathologically, AD is characterized
by the accumulation of extracellular β-amyloid (Aβ) plaques
and cytoplasmic neurofibrillary tangles (NFTs) which have
a microtubule-associated protein called tau [2]. In healthy
neurons, tau protein normally stabilizes the microtubules [3].
However, abnormal changes in brain chemistry cause tau
protein molecules to detach from microtubules and form
neurofibrillary tangles destroying the brain cells’ ability to
communicate with other cells [4].
Some recent studies reveal that AD may begin 20 years
or more before any symptoms appear and the disease is
clinically diagnosed [5]–[9]. Only after a certain stage, patients
may experience diagnostic symptoms such as deterioration in
*Data used in preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As
such, the investigators within the ADNI contributed to the design and
implementation of ADNI and/or provided data but did not participate in
analysis or writing of this report. A complete listing of ADNI investiga-
tors can be found at: http://adni.loni.usc.edu/wp-content/uploads/howtoapply/
ADNIAcknowledgementList.pdf
memory and decline in cognitive abilities when the irreversible
neurological damage already occurs. Therefore, early and
accurate diagnosis of AD is crucial and may be possible via
computer-assisted analytical techniques. Receiving an early
diagnosis of AD will enable patients to benefit from various
treatments, plan their future, and maximize their life quality.
As AD progresses, the structure of the brain undergoes some
changes, such as the shrinkage of the cerebral cortex and hip-
pocampus and the expansion of ventricles [10], [11]. Through
numerous medical imaging techniques like magnetic resonance
imaging (MRI), positron emission tomography (PET) and
computed tomography (CT), some of these changes can be
detected earlier. Notably, a T1-weighted MRI scan of the brain
reveals high-resolution structural information of the brain and
can be used to identify atrophic changes in the temporal lobes
[12].
Throughout the last decade, multiple studies have been
focusing on the automatic diagnosis of AD using different
methods [13]–[15]. Among those, deep learning (DL) has
come to the fore as one of the most promising tools to address
AD diagnosis and prognosis. In DL models, discriminative
features may be extracted automatically from the raw data
resulting in end-to-end learning design.
In this work, we propose an end-to-end AD classifier,
which takes T1 weighted MRI as input. We implemented
a 3D VGG (a deep neural network model implemented by
Oxford Visual Geometry Group (VGG)) variant convolutional
neural network (CNN) to overcome the limitations regarding
the feature extraction from brain MRI and preserve spatial
relations. Figure 1 provides an illustration of the network
architecture.
The paper is organized as follows: after this introduction, a
brief of related work is given in Section II. Section III provides
the details of the proposed model, including the dataset and
classification algorithm of CNN. Experimental results are
presented in Section IV. Finally, Section V concludes the paper
with some final remarks.
II. RELATED WORK
DL has become a popular and powerful technique with the
advance of the computational power of GPU clusters and big
data analytics, and as a result, rapidly expanded into various
fields. In medical image analysis, several neuroimaging studies
have utilized DL models for diagnosis of AD [16]–[21].
Fig. 1: Overview of the 3D convolutional neural network (CNN) architecture. 3D boxes show input and feature maps.
Various studies used a set of 2D slices extracted from the
MRI volume as input to the 2D CNN architectures [22]–
[28]. Farooq et al. [22] used a 2D CNN model for 4-way
classification of Alzheimer’s into AD, MCI (Mild Cognitive
Impairment), LMCI (Late Cognitive Impairment) and HC
(Healthy Control) using structural MRI images. Sarraf et al.
[29] utilized CNN and the famous architecture LeNet-5 to
classify functional MRI data of AD’s patients from healthy
controls. In [24], Hon et al. used VGG16 and Inception V4 to
classify AD using transfer learning. Finally, in 2019, Jain et al.
[30] presented the CNN model for the 3-way AD classification.
However, in most of these studies, it is not clear if data division
was done at the subject-level, calling into question the validity
of the results due to potential data leakage [21], [28], [31].
Another possible problem in the 2D approach is the loss of
information from 3D MRI when sliced and analyzed by 2D
convolutional filters.
Some studies addressed 3D networks to solve the issue of
insufficient information in the 2D slice-level approach [16],
[17]. Even though these models are computationally more
expensive, they have a higher capability to extract discrimi-
native features from three-dimensional MRI data. Korolev et
al. [20] used 3D residual neural network architecture together
with several regularization techniques for AD classification.
In 2018, Hosseini-Asl et al. [32], utilized a pre-trained 3D-
Adaptive CNN classifier with used scans from the CADDe-
mentia dataset for the classification of AD vs. HC. How-
ever, the details regarding CV methodology and classification
decisions are not presented in this study. Wang et al. [33]
proposed an ensemble of 3D densely connected convolutional
networks (3D-DenseNets) for three-class AD, MCI, and HC
diagnosis. In their model, MRI scans of the same patients that
are over three years apart are employed as different samples,
incorporating information of test data into the learning process.
Rieke et al. [19] trained a 3D CNN for AD classification
accuracy. At the end of their visualization efforts, they showed
that the model focuses on the medial temporal lobe. Yang et al.
[34] also provided visual explanations regarding the AD from
Deep 3D CNNs. They utilized 3D-VGGNet together with 3D-
ResNet. Finally, in 2019, Oh et al. [17] develop a volumetric
CNN-based approach for the AD classification task.
It should be noted that the classification performances of
these studies are hard to compare as they have trained and
tested the models with different sets of participants. The
studies also differ in terms of the pre-processing stages, hy-
perparameter selection, cross-validation (CV) procedure, and
evaluation metrics.
III. METHODS
In this section, the main components of our framework
are presented. We briefly describe the datasets used in the
experiments in Subsection III-A, explain the preprocessing
steps of T1-weighted MRI data in III-B and finally show
architectures of the model in III-C.
A. Datasets
In this study, we use two primary publicly available datasets
on AD and Related Dementia: the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) dataset [35] and Open Access
Series of Imaging Studies (OASIS) [36]. These datasets are
described in detail below. The characteristics of the subjects
included in this study are given in Table I.
TABLE I: Demographic information of subjects from ADNI
and OASIS datasets
Dataset Diagnosis No. Sex Age (mean ± SD)
ADNI AD 100 44 F, 56 M 74.3 ± 7.9
HC 100 52 F, 48 M 75.0 ±,7.1
OASIS AD 100 59 F, 41 M 76.7 ± 7.1
HC 100 73 F, 27 M 75.5 ± 9.1
1) ADNI: ADNI1 is a research initiative that brings together
researchers to collect, validate, and utilize several types of
data such as clinical, genetic, MRI, PET, and biospecimen to
validate biomarkers for AD [35]. ADNI is formed in 2004 and
launched three different phases so far, namely ADNI 1, ADNI
GO/2, and now ADNI 3. In addition to the first phase, ADNI
2 contains information from 150 elderly controls, 100 EMCI
subjects, 150 late mild cognitive impairment (LMCI) subjects,
and 150 mild AD patients.
In this work, we used a subset of ADNI 2 dataset with
200 structural T1-weighted MRI scans. From ADNI 2 dataset,
we randomly picked 200 subjects, 100 of whom were chosen
from the AD group (44 women and 56 men, age 74.28 ± 7.96
years, mean ± SD), while the other 100 from the HC group (52
women and 48 men, age 75.04 ± 7.11 years, mean ± SD). Only
the first scan of each patient has been added to the dataset.
Patients with a clinical dementia rating (CDR) score of 0 are
labeled as HC subjects, whereas the ones whose CDR rating
higher than 0 are considered as AD subjects. MPRAGE T1-
weighted MRI images have been acquired using 3 T scanners,
and consisted of 176 × 240 × 256 (Siemens) and 170 × 256
× 256 (Philips) voxels with a size of approximately 1 mm ×
1 mm × 1.2 mm.
2) OASIS: OASIS2 is a project that is intended to promote
future discoveries in AD by providing neuroimaging datasets
freely to the scientific community. The project released data
in three different phases: OASIS 1-Cross-sectional, OASIS 2-
Longitudinal, and OASIS-3-Longitudinal. OASIS 1 includes
overall 416 subjects (316 HC and 100 AD) aged 18 to 96.
For our experiments, T1-weighted MRI scans of 100 healthy
subjects [73 women and 27 men, age 75.5 ± 9.1 years, mean
± standard deviation (SD)] and 100 AD patients (59 women
and 41 men, age 76.7 ± 7.1 years, mean ± SD) have been
selected to create a subset of OASIS-1 dataset. Again, the
CDR score was 0 for the HC subjects, 0.5 (very mild), 1
(mild), 2 (moderate), and 3 (severe) were for the AD subjects.
MPRAGE T1-weighted MRI images have been acquired using
a 1.5 T Siemens scanner. They are in the size of 256 × 256
× 128 with voxel size 1 mm × 1 mm × 1.25 mm.
B. Data pre-processing
Even though CNN models do not require any preprocessing
beforehand, an accurate image preprocessing stage could be
key to increase the effectiveness of learning and help to
1The details regarding acquisition protocols can be found at http://adni.loni.
usc.edu/methods/documents/mri-protocols/.
2More details about the OASIS-1 data can be found at https://www.
oasis-brains.org/files/oasiscross-sectionalfacts.pdf.
(a) A sample T1-weighted MRI slices
of a Alzheimer’s disease (AD) pa-
tient from ADNI dataset after pre-
processing - in coronal, sagittal, and
axial view (left, right and bottom
respectively).
(b) A sample T1-weighted MRI
slices of a Alzheimer’s disease (AD)
patient from OASIS dataset after pre-
processing - in coronal, sagittal, and
axial view (left, right and bottom
respectively)
Fig. 2: Example of six Magnetic resonance imaging (MRI)
slices of two Alzheimer’s Disease (AD) subjects from ADNI
and OASIS databases [35], [36].
achieve a good classification performance, particularly in the
domain of MRI [37], [38]. We transformed all the data into
a standardized structure by performing co-registration with a
standard template and skull stripping.
For ADNI, each T1-weighted image has been co-registered
with the SyN method using standard T1-weighted template
MNI152 at 1 mm [39]. After co-registration, the brain mask of
the standard space has been applied to each volume to remove
extracranial tissues. The final size of the ADNI T1-weighted
MRI volumes is 182 x 218 x 182 with 1mm x 1mm x 1mm
voxel size.
When it comes to the OASIS dataset, we used the data
which was already gain-field corrected. An additional brain
masking and re-sampling operations are performed. The final
dimension of the 3D volume is 176 x 208 x 176 with 1mm
x 1mm x 1mm voxel size [40]. The sample MRI slices from
ADNI and OASIS datasets after the pre-processing stage can
be seen in Figure 2.
C. CNN Models: 3D Convolutional Networks
We created a 3D CNN model inspired by VGG-16 ar-
chitecture. The model has four convolutional blocks, among
which the first two contain two convolutional layers each, and
the latter two have three convolutional layers followed by a
pooling layer with filter size 2x2x2. The overview of the 3D
CNN architecture is shown in Figure 3. A convolutional and a
pooling layer has several feature maps, and in most cases,
the number of feature maps increases as layers grow. The
calculation of the jth feature map is given by:
yj = f(Wj ∗ x+ bj) (1)
where yj be the 3D array of the jth feature map in a hidden
layer, x be the 3D array of the input, bj be the scalar bias and
W j be the 3D filter with a size of w×h×d. f corresponds to an
activation function, and ∗ stands for the convolution operation.
Fig. 3: The architecture of the convolutional neural network
(CNN) model used in our AD classification tasks.
The convolution operation [Wj ∗x](m, p, q), is represented as
follows:
w−1∑
u=0
h−1∑
v=0
d−1∑
k=0
Wj(w−u, h−v, d−w)x(m+u, p+v, q+k) (2)
After the convolutional blocks, a dropout layer with a
probability of 0.5 is applied to avoid overfitting. It is followed
by three fully connected layers with 128, 64, and 2 neurons,
respectively. The last fully-connected layer with softmax acti-
vation provides the output label. The model has been trained
with categorical cross-entropy loss and the Adam optimizer
with a learning rate of 0.0001 and a batch size of 2 for 200
epochs. Binary cross-entropy loss is computed as:
L(y, p) = −(y log p+ (1− y) log (1− p)) (3)
where y is the actual label and p is the predicted label.
Training and validation of our proposed models were per-
formed on a NVidia RTX2080 GPU.
IV. EXPERIMENTAL RESULTS
The model has been evaluated using five-fold CV. The
average accuracy is obtained by repeating 5 times the full
5-fold cross-validation starting from five different splits of the
data into folds. The architecture was built using Keras with
TensorFlow backend [41], [42].
The model was tested on two different test sets, each
of which contains 40 subjects. Using 5-fold CV, the model
achieves 73.4%± 0.04 (mean, standard deviation) on ADNI
dataset and 69.9%± 0.06 (mean, standard deviation) clas-
sification accuracy on the OASIS dataset. The results are
comparable to other studies that use different convolutional
models for AD vs. HC classification. In addition, the dataset
is divided by subjects, and only one screening of a patient
is included in the dataset in order to prevent possible data
leakage. For instance, Rieke et al. [19] reported 78% ± 0.04
classification accuracy with a similar architecture using ADNI
1 datasets, which contains MRI scans of the subjects up to
three-time points (screening, 12 and 24 months; sometimes
multiple scans per visit). Following such procedure may cause
the scans of the same subject to be in both testing and training
set, which could affect the model performance.
V. CONCLUSION
In this work, we presented a deep 3D CNN model for
the classification of AD patients using structural brain MRI.
We demonstrated the model performance on two primary
AD datasets, namely ADNI and OASIS. Without any feature
extraction stage, the model managed to achieve 73.4%± 0.04
(mean, standard deviation) and 69.9%± 0.06 accuracy for
classification of AD subjects from HC on ADNI and OASIS
datasets respectively. In our future work, we would like to
expand this study and archive better classification accuracy
through optimizing the network shape and hyperparameters.
Moreover, we will use explainable AI techniques to investigate
which brain regions or patterns are most important to the
model and shed light on the rationale behind the model’s
predictions.
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